Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
46.74
+0.34 (0.73%)
Nov 21, 2024, 12:04 PM EST - Market open

Ultragenyx Pharmaceutical Revenue

Ultragenyx Pharmaceutical had revenue of $139.49M in the quarter ending September 30, 2024, with 42.27% growth. This brings the company's revenue in the last twelve months to $522.75M, up 27.44% year-over-year. In the year 2023, Ultragenyx Pharmaceutical had annual revenue of $434.25M with 19.52% growth.

Revenue (ttm)
$522.75M
Revenue Growth
+27.44%
P/S Ratio
7.71
Revenue / Employee
$409,675
Employees
1,276
Market Cap
4.31B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023434.25M70.92M19.52%
Dec 31, 2022363.33M11.92M3.39%
Dec 31, 2021351.41M80.38M29.66%
Dec 31, 2020271.03M167.32M161.32%
Dec 31, 2019103.71M52.22M101.41%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Oscar Health 8.22B
ICU Medical 2.34B
Integer Holdings 1.71B
Alkermes 1.51B
Haemonetics 1.36B
Prestige Consumer Healthcare 1.11B
Axsome Therapeutics 338.46M
TG Therapeutics 264.79M
Revenue Rankings